Semaglutide's patent expires in India on March 24, 2026, and generic versions could cut prices by about 90%. However, access may be limited by eligibility rules based on a BMI threshold of 27, derived from the SELECT trial's predominantly white cohort. The authors argue this threshold ignores the 'thin-fat phenotype' common in South Asian populations, who face elevated cardiovascular risk at lower BMIs. They call for India-specific evidence and guidelines to determine who should qualify for generic semaglutide.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.